Background: The variable efficacy (0-80%) of Mycobacterium bovis Bacille Calmette Gurein (BCG) vaccine against adult tuberculosis (TB) necessitates development of alternative vaccine candidates. Development of recombinant BCG (rBCG) over-expressing promising immunodominant antigens of M. tuberculosis represents one of the potential approaches for the development of vaccines against TB.
Loading...
Name
journal.pone.0003869.pdf
Type
Publisher's Version
Version
http://purl.org/coar/version/c_970fb48d4fbd8a85
Access type
openaccess
Size
2.25 MB
Format
Adobe PDF
Checksum (MD5)
f81476037839a43b384cdae86d1345b6